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PAST
Neoadjuvant therapy improves long-term survival by
providing locoregional disease control and reducing the
risk of long-term recurrence. The most important prog-
nostic factor of survival after neoadjuvant therapy followed
by surgery is the burden of lymph node involvement.
Several trials have demonstrated improved long-term sur-
vival with neoadjuvant therapy; however, there are little
data evaluating adenocarcinoma and squamous cell carci-
noma (SCC) and difference in outcomes for similar
pathological stage with and without neoadjuvant treatment.
This study1 demonstrated pathological stage provides a
better estimate of prognosis compared with clinical stage.
Downstaged patients may have an improved outcome over
those with comparable pathological stage who did not
receive neoadjuvant treatment.
PRESENT
These results corroborate what has been found in other
recent studies2,3 that disease downstaging with neoadjuvant
treatment is associated with better overall survival. This
has led to the acceptance of neoadjuvant therapy for locally
advanced esophageal cancer as the standard of care.
However, it is apparent that not all patients respond to
neoadjuvant treatment to the same degree and the observed
impact could be used to tailor adjuvant treatment. In
addition, there appeared to be better survival in patients
who received neoadjuvant therapy compared with similarly
staged neoadjuvant-naı¨ve patients. This was apparent
through all stages for SCC, and evident in more advanced
adenocarcinoma.
FUTURE
This study reinforces the understanding that post-
neoadjuvant stage influences prognosis. While some may
advocate ‘complete’ restaging prior to progressing to sur-
gery, induction therapy is known to potentially impact on
the reliability of staging modalities. It may also be
important to consider the post-neoadjuvant stage when
deciding on the merit of adjuvant treatment. There has been
some suggestion that adjuvant treatment may confer some
benefit in node-positive patients with adenocarcinoma who
received neoadjuvant chemoradiotherapy, and it already
forms part of the standard of treatment in patients receiving
MAGIC protocol chemotherapy.4 However, the ability to
predetermine the impact of neoadjuvant therapy on disease
stage based on specific biological factors of a tumor may
further individualize oncological therapy, as demonstrated
in colon cancer.5 This will guide informed decision among
patients and clinicians moving forwards.
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